Antimicrobial susceptibility of 136 Escherichia coli isolates from cases of neonatal meningitis and relationship with virulence  by Houdouin, V. et al.
RESEARCH NOTE
Antimicrobial susceptibility of 136
Escherichia coli isolates from cases of
neonatal meningitis and relationship with
virulence
V. Houdouin, S. Bonacorsi, P. Bidet and
E. Bingen
Laboratoire d’E´tudes de Ge´ne´tique Bacte´rienne
dans les Infections de l’Enfant (EA 3105),
Universite´ Denis Diderot-Paris 7, Hoˆpital
Robert Debre´ (APHP), Paris, France
ABSTRACT
The susceptibility of 136 Escherichia coli isolates
from cases of neonatal meningitis to amoxycillin,
ceftriaxone, nalidixic acid, ciproﬂoxacin and gen-
tamicin was determined in relation to the carriage
of virulence factors and phylogenetic group. Only
amoxycillin and nalidixic acid resistance was
observed (40% and 3%, respectively). Nalidixic
acid resistance alone was associated with non-
virulent phylogenetic group A (50% vs. 6% of
susceptible isolates; p 0.03). No difference in
virulence was observed between two representa-
tive nalidixic acid-susceptible virulent group B2
isolates and their nalidixic acid-resistant deriva-
tives in a rat model of neonatal meningitis,
suggesting that nalidixic acid resistance does not
affect the virulence of E. coli strains causing
meningitis.
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Escherichia coli is a major cause of meningitis in
neonates, and is associated with high rates of
mortality and morbidity [1]. Rapid diagnosis
and appropriate empirical antibacterial chemo-
therapy are essential for successful management.
The high frequency of resistance in E. coli to
aminopenicillins means that third-generation
cephalosporins are currently considered to be the
drugs of choice for treatment of E. coli meningitis
[2]. Fluoroquinolones, although not licensed for
use in infants, have proven to be safe and effective
in this setting [3]. The antibiotic susceptibility
proﬁles of E. coli isolates from neonates with
meningitis are poorly documented [4,5]. There is
some evidence that resistant E. coli strains may be
less virulent than susceptible strains, but it is not
known whether this also applies to isolates from
cases of neonatal meningitis [6–8].
The present study determined the susceptibil-
ities of 136 E. coli isolates, referred to the French
National E. coli Reference Centre between 1995
and 2005, from the cerebrospinal ﬂuid of neonates
with meningitis throughout France. Susceptibility
to nalidixic acid was tested by the disk-diffusion
method, and MICs of amoxycillin, ceftriaxone,
ciproﬂoxacin and gentamicin were determined
using the agar dilution method with CLSI inter-
pretative criteria [9]. The phylogenetic group of
all the isolates and the presence of eight putative
virulence factor genes characteristic of extra-
intestinal pathogenic E. coli strains were deter-
mined as described previously [10].
Nalidixic acid-resistant mutants of two arche-
typal group B2 E. coli strains, S95 (O45:K1:H7)
from the French collection studied, and C5
(O18:K1:H7) from the USA [10], were obtained
by inoculating dense suspensions (109 CFU ⁄mL)
of each test strain on agar plates containing
nalidixic acid 16 mg ⁄L. After incubation for
24 h, ﬁve colonies from each plate were selected
and their ciproﬂoxacin MICs were determined. To
determine the genetic mechanism of resistance,
the gyrA and parC genes were ampliﬁed from
boiled lysates and sequenced as described previ-
ously [11,12]. Two gyrA mutants (S95gyrA and
C5gyrA) with ciproﬂoxacin MICs of 0.25 mg ⁄L
were then tested in a neonatal rat model of
bacteraemia and meningitis [13]. Data were
expressed as means ± SD and were compared
using a two-sample paired t-test. Groupwise
comparisons of proportions were based on Pear-
son’s chi-squared test or Fisher’s exact test, as
appropriate, with p <0.05 considered to be statis-
tically signiﬁcant.
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The prevalence of resistance to amoxycillin and
nalidixic acid was 40% and 3%, respectively.
None of the isolates was resistant to ceftriaxone,
ciproﬂoxacin or gentamicin, with MIC90 values of
0.064 mg ⁄L and 0.032 mg ⁄L for ceftriaxone and
ciproﬂoxacin, respectively. However, the ceftriax-
one MIC for one isolate and the ciproﬂoxacin MIC
for four nalidixic acid-resistant isolates were
> ten-fold higher than the respective MIC90
values (2 and 0.5 mg ⁄L, respectively). The four
nalidixic acid-resistant isolates had a single
amino-acid change at Ser83 in GyrA and no
alterations in ParC (data not shown). No differ-
ence was observed between amoxycillin-resistant
and -susceptible isolates. Nalidixic acid resistance
was associated with phylogenetic group A (50%
vs. 6% of susceptible isolates; p 0.03) (Table 1).
No difference in the prevalence of virulence
factors between resistant and susceptible isolates
was observed.
The virulence of the two archetypal group B2
strains, S95 (O45:K1:H7) and C5 (O18:K1:H7), was
assessed in comparison with their nalidixic acid-
resistant derivatives in an experimental model of
neonatal meningitis. The resistant mutants had a
single amino-acid change at Ser83 in GyrA, which
is the most frequent mutation involved in quino-
lone resistance [12]. However, no differences in
terms of the level of bacteraemia or the frequency
of meningitis were observed between the nali-
dixic acid-resistant and nalidixic acid-susceptible
strains (Table 2).
The prevalence of virulence factors and the
phylogenetic group distribution of the E. coli
isolates from cerebrospinal ﬂuid were similar to
those reported previously [10]. Although several
studies have suggested that resistance to antibi-
otics, particularly quinolones, is associated with a
lower rate and ⁄ or reduced level of expression of
certain virulence factors by extra-intestinal path-
ogenic E. coli strains [7,8,14], the distribution of
the major phylogenetic groups and virulence
factors was similar for the amoxycillin-susceptible
and -resistant isolates Although the prevalence of
nalidixic acid resistance was low, group A was
represented signiﬁcantly more frequently among
nalidixic acid-resistant than among nalidixic acid-
susceptible isolates. Similarly, nalidixic acid resis-
tance among E. coli isolates from adults with
urosepsis has been associated with group A
[15,16]. Such a relationship could arise from an
enhanced exposure of group A strains, which
belong mostly to the faecal ﬂora [17], to antibiotics.
Table 1. Antibiotic susceptibility,
phylogenetic group and virulence
factors of 136 Escherichia coli isolates







Resistant n = 4
(%)
Susceptible n = 132
(%)
Resistant n = 54
(%)
Susceptible n = 82
(%)
Phylogenetic group
B2 108 (79) 2 (50) 106 (80) 45 (83.5) 63 (77)
D 17 (13) 17 (13) 5 (9) 12 (15)
A 10 (7) 2 (50)a 8 (6)a 4 (7.5) 6 (7)
B1 1 (1) 1 (1) 1 (1)
Virulence factorsb
Antigen K1c 125 (92) 3 (75) 122 (92) 49 (91) 76 (93)
papGII 63 (46) 1 (25) 62 (47) 27 (50) 36 (44)
papC 71 (52) 1 (25) 70 (53) 30 (55) 41 (50)
sfa ⁄ focc 49 (36) 2 (50) 47 (36) 17 (31) 32 (39)
sfaSc 43 (32) 2 (50) 41 (31) 15 (28) 28 (34)
ibeAc 53 (39) 2 (50) 51 (39) 20 (37) 33 (40)
hly 18 (13) 2 (50) 16 (12) 12 (22) 6 (7)
iroNc 104 (76) 2 (50) 102 (77) 44 (81) 60 (73)
iucC 120 (88) 4 (100) 116 (88) 45 (83) 75 (91)
ap 0.03.
bpapGII, adhesin PapG class II; papC, P ﬁmbriae; sfa ⁄ foc, S ﬁmbriae; sfaS, adhesin S; ibeA, invasin; hly, haemolysin;
iroN, iron-uptake system salmochelin; iucC, iron-uptake system aerobactin.
cVirulence factors speciﬁcally involved in meningo-virulence.
Table 2. Comparison of the virulence of nalidixic acid-
susceptible group B2 strains of Escherichia coli with their








in log CFU ⁄mL (SD)
% of animals with
culture-positive CSF
C5 Wild-type 40 5.3 (1) 31
C5gyrA gyrA mutation 20 5.3 (0.7)a 55
S95 Wild-type 18 6.4 (1.1) 39
S95gyrA gyrA mutation 18 6.2 (1.2)a 44
CSF, cerebrospinal ﬂuid.
ap >0.05 compared to wild-type.
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Another possible explanation for a higher
frequency of nalidixic acid resistance among
isolates belonging to less virulent phylogenetic
groups, such as group A, would be an incompat-
ibility between quinolone resistance and virulence
because of physical loss of virulence factor genes.
By activating the SOS response to inhibition of
DNA replication, quinolones may contribute to
the excision of bacteriophage or virulence genes
from the bacterial chromosome. Soto et al. [18]
reported that sub-inhibitory concentrations of
quinolones induced total or partial loss of a
pathogenicity island [18], although Johnson et al.
[19] failed to conﬁrm these results. Horcajada
et al. [14] found that group B2 quinolone-resistant
uropathogenic E. coli strains harboured fewer
virulence factors than their quinolone-susceptible
counterparts, but this could not be conﬁrmed in
the present study because of the low prevalence
of nalidixic acid resistance among the B2 isolates.
Alternatively, DNA gyrase mutations might
negatively regulate virulence factor expression
[20].
In the present study, the antibiotic resistance
proﬁles of the four isolates that were highly
resistant to nalidixic acid and susceptible to
ciproﬂoxacin were associated with alterations in
GyrA. However, when the virulence of two
archetypal group B2 strains, namely S95
(O45:K1:H7) and C5 (O18:K1:H7), and their nali-
dixic acid-resistant gyrA mutants with a single
amino-acid change at Ser83 was determined, the
resistant derivatives exhibited the same virulence
factors as their susceptible parents (data not
shown). The level of bacteraemia and the fre-
quency of meningitis did not differ signiﬁcantly
between the wild-type strains and their resistant
derivatives (Table 2), indicating that this particu-
lar gyrase mutation, causing the most frequent
type of quinolone resistance in E. coli [12], does
not affect virulence and had no major biological
cost, at least in the meningitis model used in this
study.
In conclusion, the low prevalence of nalidixic
acid resistance observed among the E. coli isolates
causing neonatal meningitis was in line with the
reported association between low virulence and
quinolone resistance. However, the experimental
data from the present study do not support the
hypothesis of a deleterious effect of nalidixic acid
resistance on the virulence of E. coli strains
causing meningitis. Further comparisons between
nalidixic acid-susceptible virulent strains and
their resistant mutants are needed to reinforce
this observation.
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ABSTRACT
The most prevalent strain of Mycobacterium tuber-
culosis in Madrid, Spain (strain 5) was recovered
from 45 cases between 1997 and 2004 and showed a
highly homogeneous genetic composition. This
strain was not exclusive to Spain, and its spoligo-
typing signature (ST20) was found in entries from
different countries in the SITVIT1 database.
Patients infected with strain 5 were more fre-
quently positive for human immunodeﬁciency
virus and autochthonous, and had been in prison
more frequently, but strain 5 did not show inc-
reased infectivity in an in-vitro model of infection.
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Molecular tools allow different Mycobacterium
tuberculosis (MTB) strains circulating in a popula-
tion to be distinguished, with ﬁngerprint data
obtained in molecular epidemiology programmes
[1] making it possible to identify prevalent strains
or genetic families that are over-represented in
certain settings [2,3]. In Spain, there has been a
sharp increase in the number of cases of tubercu-
losis among immigrants [4]. It is assumed that
some of these patients import MTB strains from
their countries of origin, and that such strains
could have an impact on the proﬁle of strains
circulating in the host population, considering the
high rate of transmission between the autochtho-
nous and immigrant populations in this area [4].
Molecular ﬁngerprinting tools have been used in
Madrid, Spain since 1997 [5]. The MTB isolates
from nine urban districts (1 459 232 inhabitants) in
Madrid were genotyped. Isolates from all nine
districts were genotyped during 2002–2004, and
isolates from ﬁve districts during 1997–2001.
In total, 1207 MTB isolates were analysed by
IS6110 restriction fragment length polymorphism
[6], yielding 867 different genotypes, with 455
(37.7%) isolates grouped in 115 clusters; 51.3% of
the clusters included two isolates, and only 9.6% of
the clusters included more than six isolates. Nev-
ertheless, some large clusters were detected, with
the four largest clusters corresponding to strains 5
(45 cases), 2, 8 and 38 (20 cases each). Strain 5 was
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